Oculis kynnir ný lífmerkisgögn (e. Biomarker Data) úr fasa 2 ACUITY-rannsókninni sem styðja enn frekar taugaverndandi möguleika Privosegtor við sjóntaugabólgu

Oculis announced new biomarker data from the Phase 2 ACUITY trial showing that Privosegtor reduced increases in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in blood compared to placebo in optic neuritis patients. The data supports earlier findings of improved low-contrast visual acuity and retinal structure preservation, suggesting Privosegtor's neuroprotective effects. The company plans to continue the PIONEER registration program and explore applications in acute MS relapses.